InfuSystem Holdings, Inc. INFU PHARMA
Company Overview
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Why Investors Should Care
Generates a return on equity of 15.0%, reflecting efficient use of shareholder capital.
Net profit has compounded at 14.4% per year over the last five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $143.44M (+6.4% YoY); net profit $6.63M.
- Trailing 12 Months Year-on-year growth — revenue +2.6%, earnings +25.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.5%, profit CAGR 14.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.49% |
| 1 Year: | 2.60% |
Compounded Profit Growth
| 5 Years: | 14.36% |
| 1 Year: | 25.00% |
Stock Price Performance
| 1 Year: | +27.58% |
| 6 Months: | +20.96% |
| 3 Months: | +31.96% |
| 1 Month: | -4.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.34 · Neutral
P/E of 29.72 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 14.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INFU InfuSystem Holdings, Inc. PHARMA | 11.89 | 29.72 | $239.96M | 0.00% | 14.83% | 15.03% | 8.49% | 14.36% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 17.65M | 16.94M | 17.59M | 16.48M | 16.41M | 16.68M | 18.19M | 19.72M | 21.49M | 21.55M | 26.00M | 25.12M | 24.46M | 24.83M | 26.57M | 26.76M | 27.04M | 27.28M | 30.37M | 31.73M | 31.91M | 32.00M | 33.70M | 35.32M | 34.72M | 36.00M | 36.49M | 33.68M | 36.93M |
| Gross Profit | 10.33M | 11.34M | 12.08M | 11.92M | 11.73M | 12.09M | 11.85M | 12.88M | 12.56M | 11.14M | 10.39M | 10.65M | 10.34M | 11.04M | 10.24M | 9.69M | 9.67M | 10.34M | 11.36M | 12.24M | 12.66M | 15.98M | 15.12M | 14.58M | 15.05M | 15.26M | 15.37M | 14.90M | 16.22M | 14.95M | 15.83M | 15.62M | 16.47M | 16.67M | 19.05M | 19.17M | 19.87M | 20.82M | 19.68M | 21.41M |
| Operating Income | 861.00K | 1.92M | 1.78M | 2.34M | 2.44M | 1.55M | 1.32M | 2.33M | 414.00K | 438.00K | 576.00K | -1.97M | -1.09M | 560.00K | 588.00K | -204.00K | -95.00K | -420.00K | 971.00K | 1.66M | 33.00K | 4.51M | 3.25M | 873.00K | 696.00K | -351.00K | -525.00K | 207.00K | 943.00K | -107.00K | 1.25M | 1.70M | -845.00K | 1.85M | 3.27M | 618.00K | 3.78M | 3.81M | 1.59M | 4.15M |
| Net Income | 105.00K | 649.00K | 583.00K | 886.00K | 852.00K | -415.00K | 783.00K | 1.14M | 41.00K | 153.00K | 56.00K | -1.48M | -1.11M | -129.00K | 204.00K | -505.00K | -519.00K | -960.00K | 381.00K | 1.14M | -418.00K | 4.14M | 2.94M | 661.00K | 820.00K | -448.00K | -368.00K | -164.00K | 443.00K | -324.00K | 435.00K | 689.00K | -1.11M | 717.00K | 1.81M | -267.00K | 2.60M | 2.26M | 1.02M | 3.23M |
| Diluted EPS | 0.00 | 0.03 | 0.03 | 0.04 | 0.04 | -0.02 | 0.03 | 0.05 | 0.00 | 0.01 | 0.00 | -0.07 | -0.05 | -0.01 | 0.01 | -0.02 | -0.03 | -0.05 | 0.02 | 0.05 | -0.02 | 0.19 | 0.14 | 0.03 | 0.04 | -0.02 | -0.02 | -0.01 | 0.02 | -0.02 | 0.02 | 0.03 | -0.05 | 0.03 | 0.08 | -0.01 | 0.12 | 0.11 | 0.05 | 0.15 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.96M | 47.23M | 54.64M | 58.83M | 62.28M | 66.49M | 70.54M | 70.50M | 71.08M | 67.14M | 81.11M | 97.39M | 102.38M | 109.91M | 125.78M | 134.86M | 143.44M |
| Gross Profit | 28.64M | 33.55M | 35.35M | 42.91M | 43.68M | 47.35M | 49.60M | 44.74M | 43.36M | 39.57M | 46.88M | 58.76M | 58.54M | 60.56M | 63.11M | 70.40M | 80.30M |
| Operating Income | 5.33M | -938.00K | -66.36M | 2.00M | 5.90M | 9.33M | 7.28M | 974.00K | -3.81M | 415.00K | 3.52M | 8.83M | 2.82M | 1.65M | 4.09M | 6.89M | 11.92M |
| Net Income | 774.00K | -1.85M | -45.44M | -1.49M | 1.67M | 3.36M | 2.79M | -222.00K | -20.71M | -1.09M | 1.36M | 17.33M | 1.42M | 18.00K | 872.00K | 2.35M | 6.63M |
| Diluted EPS | 0.04 | -0.09 | -2.16 | -0.07 | 0.08 | 0.15 | 0.12 | -0.01 | -0.91 | -0.05 | 0.07 | 0.80 | 0.06 | 0.00 | 0.04 | 0.11 | 0.31 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 130.36M | 76.26M | 77.52M | 77.37M | 80.21M | 95.36M | 96.34M | 68.88M | 64.07M | 79.22M | 96.99M | 97.59M | 99.39M | 102.92M | 103.61M | 100.56M |
| Total Equity | 80.07M | 81.47M | 85.14M | 40.16M | 40.01M | 42.72M | 46.45M | 50.32M | 50.69M | 30.95M | 20.44M | 22.33M | 40.75M | 48.27M | 48.00M | 52.30M | 57.53M | 57.33M |
| Cash & Equivalents | 11.51M | 7.75M | 5.01M | 799.00K | 2.33M | 1.14M | 515.00K | 818.00K | 3.40M | 3.47M | 4.32M | 2.65M | 9.65M | 186.00K | 165.00K | 231.00K | 527.00K | 3.19M |
| Long Term Debt | - | - | 26.65M | 22.55M | 27.32M | 21.61M | 19.03M | 26.55M | 26.58M | 25.35M | 28.84M | 30.30M | 29.38M | 32.75M | 33.16M | 29.10M | 23.86M | 19.62M |
| Total Liabilities | - | - | 45.22M | 36.10M | 37.51M | 34.65M | 33.76M | 45.04M | 45.66M | 37.93M | 43.63M | 56.89M | 56.24M | 49.31M | 51.38M | 50.61M | 46.09M | 43.23M |
| Current Liabilities | - | - | 12.38M | 13.13M | 10.20M | 13.04M | 14.73M | 15.26M | 16.44M | 12.47M | 14.79M | 21.85M | 23.00M | 12.90M | 14.47M | 15.71M | 17.66M | 20.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 9.71M | 10.81M | 6.75M | 5.45M | 7.46M | - | - | 7.91M | 7.72M | 11.39M | 13.88M | 20.28M | 18.32M | 17.52M | 11.22M | 20.46M | 24.41M |
| Investing Cash Flow | -4.61M | -19.06M | -5.13M | -2.56M | -2.16M | - | - | -5.34M | 918.00K | -4.98M | -19.64M | -12.16M | -21.32M | -11.48M | -6.73M | -13.24M | -6.79M |
| Financing Cash Flow | -8.86M | 5.51M | -5.83M | -1.37M | -6.49M | - | - | 15.00K | -8.56M | -5.56M | 4.10M | -1.12M | -6.46M | -6.06M | -4.42M | -6.92M | -14.96M |
| Capital Expenditure | - | - | - | - | -4.72M | -2.00M | -314.00K | -168.00K | -104.00K | -281.00K | -2.93M | -1.09M | -980.00K | -982.00K | -1.02M | -1.09M | -560.00K |
| Free Cash Flow | - | - | - | - | 2.74M | - | - | 7.74M | 7.61M | 11.11M | 10.95M | 19.19M | 17.34M | 16.54M | 10.20M | 19.37M | 23.85M |
| Share Buybacks | - | 68.00K | 363.00K | 144.00K | 79.00K | 204.00K | 179.00K | 75.00K | - | 10.39M | 0 | 0 | 560.00K | 5.46M | 153.00K | 1.18M | 9.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.5% | 71.0% | 64.7% | 72.9% | 70.1% | 71.2% | 70.3% | 63.5% | 61.0% | 58.9% | 57.8% | 60.3% | 57.2% | 55.1% | 50.2% | 52.2% | 56.0% |
| Operating Margin % | 13.7% | -2.0% | -121.4% | 3.4% | 9.5% | 14.0% | 10.3% | 1.4% | -5.4% | 0.6% | 4.3% | 9.1% | 2.8% | 1.5% | 3.2% | 5.1% | 8.3% |
| Net Margin % | 2.0% | -3.9% | -83.2% | -2.5% | 2.7% | 5.0% | 3.9% | -0.3% | -29.1% | -1.6% | 1.7% | 17.8% | 1.4% | 0.0% | 0.7% | 1.7% | 4.6% |
| ROE % | 1.0% | -2.2% | -113.1% | -3.7% | 3.9% | 7.2% | 5.5% | -0.4% | -66.9% | -5.4% | 6.1% | 42.5% | 2.9% | 0.0% | 1.7% | 4.1% | 11.6% |
| ROCE % | - | -0.8% | -105.1% | 3.0% | 9.2% | 14.2% | 9.1% | 1.2% | -6.8% | 0.8% | 6.1% | 11.9% | 3.3% | 1.9% | 4.7% | 8.0% | 14.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.86% | 1.59M | $20.37M |
| 2 | Minerva Advisors LLC | 6.68% | 1.35M | $17.33M |
| 3 | Punch & Associates Investment Management, Inc. | 4.14% | 834.75K | $10.73M |
| 4 | Vanguard Capital Management LLC | 3.92% | 790.77K | $10.16M |
| 5 | Acadian Asset Management. LLC | 3.68% | 743.15K | $9.55M |
| 6 | Heartland Advisors Inc. | 3.47% | 700.00K | $8.99M |
| 7 | American Century Companies Inc | 3.34% | 675.03K | $8.67M |
| 8 | First Eagle Investment Management, LLC | 3.07% | 620.00K | $7.97M |
| 9 | Dimensional Fund Advisors LP | 2.97% | 599.29K | $7.70M |
| 10 | Renaissance Technologies, LLC | 2.69% | 543.01K | $6.98M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INFU
Unique Payer Network Strengthens InfuSystem (INFU) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNeEJaZzk4SUZBR1R0SXY4TFJDUXg2YVUyU25oTVJCUERzUjdNejA1QXUyTjJtclZoY2ZNVzdBbVRHMDlYWWcxa1NkQUxKTFptenFDZlNjai0zZWFVUV9DNXR2Y0lQbENZc0FNc1UwNU1Gb2c4VDVRR3dvYmViQmUzLWVGRURrOUotTDN6a0…
Should Value Investors Buy InfuSystems Holdings (INFU) Stock? - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPMTRackRxUjRFQ1Ewd0l2cWtPMzBXTVl2b0FHdy0zczR3V2JNbE1sNzFCWjZwQTNEaWVxSXh3ZHNiMjRIZnBJb2d0QThNUks0Vmk3U2JaU0pZb05HZjJrTTl0NjIwOGVpMVpRcVdBZVRRa1FRZ2s3Y2dJdlRXb005TGNWSjVveGFCbGtVTW…
InfuSystem: A Good Time To Buy Before A Potential Breakout - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNZjdyLXJ1aEJ2ZDNyWTljZkdKR0ZIS3BlXy1QczJEbHdRWE5MZTZEc0VPakFFSGhhangwVWtVUXZRcjBLNkJkZTBDdjlIaGtaSDNlLTVDMExaTm5WSW9oT2xUR0lSVXZoaDZ2cW93ZVlTMDM1d2NnOXJFQlJoaFV3dUhHV0wyRlBsT3JobV…
Are Investors Undervaluing InfuSystems Holdings (INFU) Right Now? - qz.com
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQQ1B1MVhkTENTMmJmcmhXR3FPLXVmcEVXUmkxZzAycVBnVHhORlNla3NpTFhxQlE0T1ZIdVJiYVFud05LS1Uyb2JBWDEyWTNLSGFXOEV4VmJ0U1RUb2M1aVV6bEZER2tsZG9wci1saVFqWnpxRWU1LTd2cVJ0ck1ZVHhjNA?oc=5" targe…
INFU | InfuSystem Holdings, Inc. Financials - Revenue Breakdown - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5HRTZPUmQzN2JYZU5xYkZ0MlFTeVZWZ25tZTNsdTRyZHZzdjlKTnNYdW5fNEY0X1REYnFLZElRR0Y4dmtaM3QyQXBhWFZwLTVUbUZvSEN0ZGxOd1JWcnlSQWl4ZjR0elR5MHdqQktKbzVQVmRfekFV?oc=5" target="_blank">INFU | …
InfuSystem Announces $20 Million Stock Repurchase Program - Business Wire
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOdFZVT0xYT2Rzd2pFdGg0ekFiUTh1eTNIZ0ZqQ0xuZ09Pd0RmOThEdTJpY0ZEUzk5Q0JuSHNEdF90VnpOUkd1Uko0bW9FSC1hVllObTJDbWlIMmRQeVNQOS1pSmRxZk92MTFaMFZwNTVVUFp0WnNhUG9nd3Fxa3dYVzU5ZjhkaE1sRFg5dl…
INFU — Frequently Asked Questions
What is the current share price of InfuSystem Holdings, Inc. (INFU)?
As of 2026-09-19 21:16 PDT, InfuSystem Holdings, Inc. (INFU) trades at $11.89 on NYSE American. Its 52-week range is $7.42 to $12.49.
What is the market capitalisation of INFU?
InfuSystem Holdings, Inc. (INFU) has a market capitalisation of $239.96M on NYSE American.
What is the P/E ratio of INFU?
INFU trades at a trailing price-to-earnings (P/E) ratio of 29.72. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.33.
What is the return on equity (ROE) of INFU?
INFU has a return on equity (ROE) of 15.03%. Its return on capital employed (ROCE) is 14.83%.
Is INFU a good stock to buy?
This page provides a data-driven analysis of InfuSystem Holdings, Inc. (INFU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.